The company said that the application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.
The company claims that the essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes.
David Koos, CEO of Entest, said: “To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy.
”The current patent application has uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry.”